| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
D1 Receptor D5 Receptor 5-HT2 Receptor 11 nM (Ki)
SKF-83566 targets D1-like dopamine receptors (D1 and D5) as a potent antagonist. It shows selective inhibition of D1-like receptors. The compound is also a weaker competitive antagonist at the vascular 5-HT2 receptor with a Ki of 11 nM. Additionally, it is a competitive dopamine transporter (DAT) inhibitor with an IC50 of 5.7 μM. By blocking D1-like dopamine receptors, the compound modulates dopaminergic signaling pathways involved in motor function, reward, and cognition. |
|---|---|
| ln Vitro |
When single-pulse stimulation is applied, SKF-83566 (0.1 μM–10 μM) increases peak evoked extracellular DA concentration ([DA]o) in a concentration-dependent manner. Peak increases of up to 65% are observed when 5 μM is applied. For this effect, SKF-83566 has an EC50 value of 1.3 μM[2]. The [3H]DA uptake is inhibited by SKF-83566, with an IC50 of 5.73 μM. Moreover, tests on [3H]DA uptake and [3H]CFT binding show that SKF-83566 inhibits [3H]CFT binding more successfully, with an IC50 of 0.51 μM [2]. Likewise, with an IC50 of 0.77 μM, SKF-83566 also prevented [3H]CFT binding in LLc-PK-rDAT cell membrane preparations [2].
In vitro, SKF-83566 acts as a potent D1-like dopamine receptor antagonist. Its activity is typically assessed by measuring its ability to inhibit dopamine-stimulated cAMP accumulation in cells expressing D1 or D5 receptors. The compound shows a Ki of 11 nM at the vascular 5-HT2 receptor and an IC50 of 5.7 μM at the dopamine transporter. Standard in vitro assays include receptor binding studies, cAMP accumulation assays, and dopamine uptake inhibition assays. The compound is used to study D1 receptor function and dopaminergic signaling pathways. |
| ln Vivo |
SKF 83566 (oral; 20 μg/mL; 7 days) did not change LTP (115%) in any way. SKF 83566 + nicotine + cocaine, 120%; nicotine + cocaine, 143%), however, significantly inhibited the increase of long-term synaptic potentiation (LTP) caused by nicotine pretreatment[1].
In vivo, SKF-83566 is blood-brain permeable and orally active, making it suitable for systemic administration in animal models. It has been used in research to study Parkinson's disease and nicotine craving. As a D1-like receptor antagonist, it would be expected to modulate dopaminergic signaling and affect motor function, reward, and cognitive processes. The compound has been shown to block effects by oral administration. However, comprehensive in vivo efficacy data from published literature are limited. |
| Enzyme Assay |
For non-cell-based receptor binding assays, SKF-83566 can be evaluated using membrane preparations from cells expressing human D1 or D5 dopamine receptors or 5-HT2 receptors. Radioligand binding displacement experiments are performed using suitable radiolabeled ligands such as [3H]-SCH23390 for D1-like receptors or [3H]-ketanserin for 5-HT2 receptors. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand at room temperature for 60-90 minutes. Bound radioligand is separated from free by rapid filtration through glass fiber filters. Non-specific binding is determined in the presence of excess unlabeled ligand. Ki values are calculated from displacement curves using nonlinear regression analysis.
|
| Cell Assay |
For in vitro cellular assays, cells expressing human D1 or D5 dopamine receptors are cultured in appropriate media. For functional assays, cAMP accumulation is measured. Cells are treated with various concentrations of SKF-83566 in the presence of a D1-like receptor agonist such as dopamine or SKF-38393. cAMP levels are measured using ELISA or HTRF-based detection. The compound's ability to inhibit agonist-induced cAMP accumulation is assessed, and IC50 values are calculated from dose-response curves. For dopamine transporter assays, cells expressing DAT are incubated with [3H]-dopamine in the presence or absence of the compound, and uptake is measured.
|
| Animal Protocol |
Animal/Disease Models: Male C57BL6/J mice (6- to 9-wk-old)[1]
Doses: 20 µg/mL (Together with nicotine for 7 d, followed by the injection of cocaine) Route of Administration: Oral administration; 7 days Experimental Results: Blocked nicotine and cocaine-induced facilitation of LTP. For in vivo animal studies, SKF-83566 can be administered to rodents via oral gavage or intraperitoneal injection. In models of Parkinson's disease, motor function and dopamine-mediated behaviors are assessed following compound administration. In models of nicotine craving, the compound's effects on drug-seeking behavior are evaluated. Dosing regimens vary depending on the specific model and desired exposure levels. Blood and tissue samples may be collected for pharmacokinetic analysis. |
| ADME/Pharmacokinetics |
SKF-83566 has a molecular weight of 374.27 and a molecular formula of C19H20BrNO2. It is a potent, blood-brain permeable and orally active D1-like dopamine receptor antagonist. The compound is soluble in DMSO and can be formulated for both in vitro and in vivo administration. It should be stored at -20°C for long-term stability. It is for research use only and is not intended for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of SKF-83566 has not been extensively reported. As a D1-like dopamine receptor antagonist, potential adverse effects may include modulation of dopaminergic signaling, which could affect motor function, reward processing, and cognition. The compound is for research use only and is not intended for human consumption. Standard toxicological evaluation would include acute and repeated-dose toxicity studies, as well as assessment of effects on the central nervous system and cardiovascular function.
|
| References |
|
| Additional Infomation |
8-Bromo-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzozazepine-7-ol is a benzozazepine.
SKF-83566 (CAS 99295-33-7) is a potent, blood-brain permeable and orally active D1-like dopamine receptor antagonist and a weaker competitive antagonist at the vascular 5-HT2 receptor (Ki = 11 nM). It is also a competitive dopamine transporter (DAT) inhibitor with an IC50 of 5.7 μM. SKF-83566 is used in research to study Parkinson's disease and nicotine craving. It is available for research purposes only. |
| Molecular Formula |
C17H18BRNO
|
|---|---|
| Molecular Weight |
332.23
|
| Exact Mass |
367.034
|
| CAS # |
99295-33-7
|
| Related CAS # |
SKF-83566 hydrobromide;108179-91-5
|
| PubChem CID |
1243
|
| Appearance |
Off-white to light yellow solid powder
|
| Boiling Point |
447.5ºC at 760mmHg
|
| Flash Point |
224.4ºC
|
| LogP |
4.514
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
318
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1CCC2=CC(=C(C=C2C(C1)C3=CC=CC=C3)O)Br
|
| InChi Key |
XFTVOHWWEQGXLS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18BrNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3
|
| Chemical Name |
8-bromo-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 33.33 mg/mL (100.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0100 mL | 15.0498 mL | 30.0996 mL | |
| 5 mM | 0.6020 mL | 3.0100 mL | 6.0199 mL | |
| 10 mM | 0.3010 mL | 1.5050 mL | 3.0100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
